SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday,